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ABSTRACT 
 
Malaria is a major threat to the public health worldwide as it is affecting populations in 
tropical and subtropical areas globally. Among those populations are around 40% of pregnant 
women and children who are susceptible to this disease. Plasmodium falciparum is the most 
lethal agent that causes malaria in human. Currently, there is drug resistance against antimalarial 
drugs in parasite against treatment of malaria infections, it is essential to search for new drug 
targets in order to find cure and alleviate suffering of human population.  
There are approximately 100 protein kinases in P. falciparum that are involved in 
phosphorylation of asexual blood stage. Hence, the phosphorylation plays an important part in 
the development of different stages of malarial parasites. Due to their significance in the parasite 
life cycle, one of the protein kinase of P. falciparum belongs to the ABC-1 family of proteins. 
PfABCK2 can be a therapeutic target due to its higher expression during the late schizont stage 
of blood stage form. 
The bioinformatic analysis and preliminary results of PfABCK2 showed the heterologous 
expression of this protein. Hence, the gene of PfABCk2 was ligated into pET21a+ vector with 
His-tag at C-terminus and transformed into BL-21 (DE3) competent cells that were verified 
through Miniprep and DNA sequencing. Furthermore, this gene construct is utilized to 
heterologous express this protein with IPTG and afterwards purified the recombinant protein 
kinase using nickel affinity chromatography as shown on 10% SDS-PAGE with the expected 36 
kDa protein band.  Therefore, the aim of this study is to partially characterize PfABCK2 protein 
kinase utilizing molecular cloning, heterologous express and protein kinase activity assay. 
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CHAPTER ONE 
INTRODUCTION 
Malaria 
Malaria is a disease that is a major threat to the public health worldwide. It is affecting 
populations in tropical and subtropical areas globally (Figure 1); especially the population 
includes pregnant women and children who are susceptible to this disease (W.H.O., 2017). 
Plasmodium falciparum is the most aggressive agent that causes malaria in human. According to 
World Health Organization (W.H.O.), it is one of the deadly vector borne- diseases globally; 
there were 216 million new cases of malaria globally in 2016 with an approximate 445,000 
deaths worldwide. The incidence rates of malaria dropped by 21% worldwide and the mortality 
rates were reduced by 29% globally between 2010 and 2015. The children under five years of 
age are the vulnerable population in which infection and death occurs due to malaria. Malaria 
caused death of 303,000 children under the age of five worldwide and the mortality rate in 
children is estimated to be 35% (W.H.O., 2017). 
W.H.O. recommends Artemisinin Combination Therapy (ACT) as first-line of treatment 
against malaria caused by P. falciparum and around 337 million people infected with malaria 
used ACT in 2014. Due to the bed-nets that were insecticide-treated and ACT, there has been 
reduction in the number of mortality and morbidity globally (Ataide et al., 2017).  
2 
 
  
Figure 1: Global distribution of malaria infection cases. World Malaria Report, 2017, W.H.O 
(See Appendex A) 
 
Epidemiology 
Malaria is a vector-borne disease and the agent for malaria is microorganism of the genus 
Plasmodium. The vector for the malarial parasite is genus Anopheles female mosquito. The 
known reservoir are humans but now mammals specifically macaque monkeys have been found 
to be reservoir for zoonotic malaria. The host of malarial parasite are birds, reptiles, mammals 
and humans ((C.D.C.), 2015). ((C.D.C.), 2015) ((C.D.C.), 2015). Therefore, the((C.D.C.), 
2015)idity, rainfall and temperature. Globally, the regions where it is transmitted are tropical and 
subtropical where the mosquito vectors ((C.D.C.), 2015) and survive and the parasite can 
complete its lifecycle within mosquitoes ((C.D.C.), 2015). The transmission of malaria does not 
occur in deserts, colder regions, high altitude regions and the countries where control and 
elimination programs are successful. On the contrary, transmission is annual in warmer and 
equatorial regions ((C.D.C.), 2015). In United States and Western Europe, malaria has been 
eradicated due to successful public health prevention and control strategies but still there is a risk 
for relapse of this disease . 
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Symptoms 
The symptom of the infection with malaria consists of asymptomatic to mild to severe and if left 
untreated sometimes lethal. Based on the symptoms, malaria is classified into uncomplicated and 
complicated ((C.D.C.), 2015). The clinical symptoms indicated are due to the blood stage or 
asexual intraerythrocytic parasites. These intraerythrocytic parasites developing inside the 
erythrocyte produce toxic substances and once these erythrocytes are lysed, these inflammatory 
substances trigger cytokines release that causes rigors, fever and other symptoms of malaria 
((C.D.C.), 2015).  
The incubation time of the infection begins after the bite of the female Anopheles 
mosquito. This incubation time can be from 7 to 30 days. Most commonly, P. falciparum 
infection has shorter incubation period and P. malariae have longer periods ((C.D.C.), 2015). On 
the other hand, P. vivax and P. ovale are the malarial parasites that can remain dormant as liver 
stage in the form of hypnozoites and reactivate causing the disease even after months or years 
after the infecting mosqito bite ((C.D.C.), 2015).  
As mentioned, malaria clinical symptoms, classicially known collectively as the 
paroxysm, present as a repeating cycle of fever and chills intersperesed with perods relative 
calm.  Based on their severity these symptoms are classified as uncomplicated malaria and 
complicated malaria. Uncomplicated malaria disease occurs for 6 – 10 hours and has different 
stages. The cold stage consists of shivers and cold, the hot stage comprises of headaches, fever, 
vomiting and the sweating stage have sweats, lethargy and normalization of temperature.   
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On the other hand, complicated malaria occurs with metabolic abnormalities and organ 
failure that include sever anemia, cerebral malaria, acute kidney failure, low blood pressure, 
acute respiratory distress syndrome (ARDS), hyperparasitemia (more than 5% RBCs), 
hypoglycemia and metabolic acidosis ((C.D.C.), 2015). 
 
Diagnosis 
The suspected case of malaria can be diagnosed on the basis of symptoms, travel history and 
laboratory diagnosis. It is a challenge to diagnose malaria based only on symptoms. The clinical 
diagnosis, microscopy, serology, rapid diagnostic test, PCR, antigen detection and drug resistant 
tests are available ((C.D.C.), 2015). The traditional gold standard for diagnosis is the Gemsa-
stained blood smear. 
 
Treatment 
According to the World Health Organization (W.H.O.), treatment of malaria patients with first 
signs and symptoms should begin within 24 hours. The treatment depends on the origin of the 
country of malaria, clinical status, pregnancy, and species type of Plasmodium and antimalarial 
drug resistance((C.D.C.), 2015).  
The uncomplicated malaria patients are treated on outpatient and severe malaria patients 
have to be hospitalized. In order to be treated with antimalarial drugs, there are different drugs 
available. These antimalarial drugs include:  
• chloroquine and mefloquine are not effective in most parts globally 
• atovaquone-proguanil  
• artemether-lumefantrine  
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• quinine  
• quinidine  
• doxycycline  
• clindamycin   
• artesunate 
Apart from these drugs, primaquine is used against liver dormant stage form 
(hypnozoites), P.vivax and P.ovale relapses. Pregnant women should not be given primaquine or 
patients deficient in glucose-6-phosphate dehydrogenase ((C.D.C.), 2015). Artemisinin 
combination therapy (ACT) is the first line of treatment against malaria caused by P. falciparum 
(Ataide et al., 2017). 
 
Anopheles 
Malaria is transmitted by the bite of a vector mosquito belonging to genus Anopheles. Among 
430 species, only 40 mosquito species are vectors of malaria. The female Anopheles mosquito 
bites the host mainly human ((C.D.C.), 2015; Phillips et al., 2017). Furthermore, the only 
mosquito that transmits malaria to humans are Anopheles (Mitchell et al., 2015). Anopheline 
mosquito species possess the vectorial capacity, the ability of the mosquito to transmit the agent 
Plasmodium to host causing malaria. This capacity is dependent on several factors of mosquito 
biology including immune responses against parasite, population densities of mosquito, 
longevity, reproductive success and blood-feeding behavior (Mitchell et al., 2015). 
The females of anopheline species are monandrous with a single mating event for reproduction 
and usually in swarms (Mitchell et al., 2015). In case of primary malaria vector of sub-Saharan 
Africa, Anopheles gambiae, males produce male seminal secretions that contain a large titers of 
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20-hydroxyecdysone that change the female mosquito physiology rendering it to reduced further 
copulation simultaneously egg production is increased and egg laying is triggered (Mitchell et 
al., 2015). This lipid transporter had a profound effect on Plasmodium development, linking 
reproductive and immune responses, reduction in the capability of mosquito immune system to 
kill parasite. This in turn increases malaria transmission, swarming behavior reduces the risk of 
predation and multiple mating is reduced(Mitchell et al., 2015).  
 
Plasmodium 
The parasite that causes malaria are Plasmodium species belong the phylum Apicomplexa. These 
are eukaryotes and single cell organism (Florens et al., 2002; Gardner et al., 2002; Winzeler, 
2009). It has apical complex involved in invasion of host cell (Phillips et al., 2017). There are at 
least five Plasmodium species that regularly infect humans. These include P. falciparum, P. 
vivax, P. ovale, P. malariae and P. knowlesi. However, P. knowlesi  is a zoonotic malaria that is 
a simian parasite transmitted to humans through infected mosquitoes (Shearer et al., 2016).  
The largest public health issue of global malaria is caused by P. falciparum and P. vivax. 
The major infective and aggressive human parasite is P. falciparum causing sub-Saharan Africa 
malaria mortality and morbidity. Moreover, it causes severe malaria and malaria associated 
pregnancy complications. Furthermore, P. falciparum contributes to 1,200 deaths of children <5 
years of age per day in Africa (Phillips et al., 2017).  
Globally, the geographical distribution of P. falciparum is in tropical areas whereas P. 
vivax is distributed in tropical and temperate areas of Southeast Asia, Central and South 
America. Due to the absence of the Duffy antigen on the membrane of erythrocytes in African 
human population, provides resistance to P. vivax malaria (Phillips et al., 2017). On the other 
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hand, the geographic distribution of P. ovale is in Asia and Africa and P. malariae is prevalent 
worldwide specifically in West Africa. The P. knowlesi, previously considered non-human 
parasite causes severe malaria and fatal complications in many parts of Southeast Asia. The co-
infections due to P. vivax and P. falciparum are reported in up to 10 -30 % of human population 
in prevalent areas (Phillips et al., 2017). 
 
Life cycle  
Malaria transmission occurs through the bite of female Anopheles mosquito infected with 
Plasmodium species (Cowman, Healer, Marapana, & Marsh, 2016; Miller, Ackerman, Su, & 
Wellems, 2013; White et al., 2014). The life cycle of Plasmodium (Figure 2) can be divided into 
two major cycles of Sporogony cycle (mosquito) and Schizogony cycle (mammalian or 
human)(Phillips et al., 2017).  
The infected mosquitoes take a blood meal then simultaneously injects sporozoite with 
saliva containing anticoagulant (Figure 2). The sporozoites of Plasmodium species are motile 
and infective stage that travels from the site of bite in skin then to lymphatic system and 
eventually transfer to liver hepatocytic cells (Phillips et al., 2017). These sporozoites multiply in 
the hepatocytes and produces merozoites which is the part of Schizogony cycle. Afterwards, the 
merozoites enter the blood-stream which is the erythrocytic schizogony stage that infect 
erythrocytes and multiply inside the cells (Baker, 2010; Waters, 2016).   
Some of the intraerythrocytic stages differentiate into sexual stage male and female 
gametocytes that are taken up by mosquito through blood-meal to complete the cycle of infection 
(Phillips et al., 2017). After initial bite of infected mosquito, the diagnostic symptoms appear in 
7 – 10 days. There are dormant forms of P. ovale and P. vivax which are hypnozoites that occurs 
8 
 
in liver of hosts. These hypnozoites dormant liver stage can reactivate and cause disease after 
months of initial bite that leads to relapse (Phillips et al., 2017; White, 2011). 
 
 
Figure 2 : Life cycle of Plasmodium species in Anopheles and human host. This image is 
obtained from Centers for Disease Control and Prevention, Global Health, Division of Parasitic 
Diseases and Malaria. https://www.cdc.gov/malaria/about/biology/index.html  ((C.D.C.), 2015). 
(See Appendex A) 
 
Artemisinin resistance 
Global malaria mortality and morbidity has been on downward path due to utilization of 
insecticide-treated bed-nets and artemisinin combination therapy (ACT) (Ataide et al., 2017; 
W.H.O., 2017). However, P. falciparum is still infecting 212 million new cases with 490,000 
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deaths per year globally ((WHO), 2017). The significant role is played through the inception of 
chemotherapeutic drug artemisinin and derivatives of artemisinin (Nsanzabana, Djalle, Guerin, 
Menard, & Gonzalez, 2018). Since 1970s, the derivatives of artemisinin had been effective anti-
malarial drugs even though it has a very short half-life. These derivatives in combination with 
anti-malarial drugs that have long half-life reduces the parasite population (Nsanzabana et al., 
2018).  
The artemisinin combination therapy (ACT) has been introduced and recommended from 
World Health Organization (WHO) since 2006 as a strategy to control and treat P. falciparum 
derived malaria (Ataide et al., 2017; Duffey, Sanchez, & Lanzer, 2018; W.H.O., 2017). 
However, P. falciparum has shown ACT resistance since 2007 and have been reported in 
western Cambodia which has expanded to all Southeast Asian countries (Ataide et al., 2017; 
Duffey et al., 2018).  
The anti-malarial drug resistance is the capability of the parasite to multiply and survive 
the dose of drug at or above the recommended dosage but tolerable to humans (Nsanzabana et 
al., 2018). Prior to artemisinin, the first drug synthetized was chloroquine initiated in 1940s. 
Afterwards, P. falciparum became resistant against chloroquine in 1960s in various geographical 
areas (Nsanzabana et al., 2018). Simultaneously, resistance against chloroquine in P. vivax 
appeared in 1980s in Indonesia, Papua New Guinea and other parts of the world. However, 
chloroquine is utilized for the treatment of P. vivax (Nsanzabana et al., 2018).  
The specific mechanism of resistance is not well-understood. However, the resistance of 
P. falciparum has been linked to propeller domain of kelch protein and gene point mutations that 
is located on chromosome 13 (Ariey et al., 2014; Straimer et al., 2015) Furthermore, after 
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artemisinin treatment the long parasite clearance half-life (PCt1/2) and kelch13 point mutations 
have been identified as artemisinin resistance molecular markers (Ataide et al., 2017).  
These resistance molecular markers have been reported by the Tracking Resistance to 
Artemisinin Collaboration (TRAC) found in Southeast Asia except Africa (Ataide et al., 2017). 
Apart from molecular markers, clearance of parasite from body is dependent on variations 
between individuals and reaction to anti-malarial drugs rely on life cycle stage of P. falciparum, 
immunity level of host and pharmacokinetics of the patients (Ataide et al., 2017). Due to 
continued exposure to malaria, natural acquired active immunity occurs quickly in high 
transmission regions as compared to low transmission (Ataide et al., 2017).  
The resistance against anti-malarial drugs surveillance involves parasite molecular targets 
linked with resistance, evaluation of sensitivity of parasite towards drugs and failures in 
treatment determination. Therefore, it  has become urgency to develop concrete surveillance 
systems and novel tools to provide detection of artemisinin resistance (Nsanzabana et al., 2018).   
 
Protein kinase ABCk subfamily 
General characteristics 
The first protein kinase was discovered by Krebs, Fischer and Graves and reported that it 
requires to be phosphorylated in order to be active (Krebs, Graves, & Fischer, 1959). 
Furthermore, Fischer reported protein kinase A (PKA) that phosphorylates phosphorylase kinase. 
Phosphorylation/ dephosphorylation is a mechanism of protein kinase superfamily to regulate 
their function (Newton, 2003). The superfamily of protein kinases consists of approximately 500 
kinases. The protein kinases consists of 12 conserved subdomains folding into a conserved core 
in the catalytic domain (Mobitz, 2015).  
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The domain close to the active site of tyrosine and serine/threonine kinases is called 
activation loop that must be phosphorylated for catalytic activity. There are three major types of 
protein kinases A (PKA), B (PKB)/(Akt) and C (PKC) that have biological function in a cell 
where cascade of phosphorylation  are involved as well as phosphorylation of activation loop 
(Newton, 2003). In general, the protein kinases consists of a kinase core, activation loop site, 
turn motif and the hydrophobic motif and these segments are conserved in all the protein kinases 
(Newton, 2003). The conserved kinase core is regulated through regulatory moiety. The 
regulatory moiety has two major functions which includes cellular location and autoinhibitory 
module of kinases. Apart from this, there are cofactors required for each protein kinases that is 
cAMP for PKA, phosphatidylinositol 3,4,5 triphosphate (PIP3) and diacylglycerol (DAG) for 
PKC (Newton, 2003). 
The cascade mechanism is dependent on phosphoinositide-dependent kinase-1 that is 
involved in cell signaling mechanism. The protein kinases are regulated through two step 
mechanisms of phosphorylation and second messengers for the activity of these enzymes. The 
first mechanism is phosphorylation and afterwards the binding of second messengers that opens 
up the substrate-binding site with the removal of R subunit or pseudosubstrate sequence 
(Newton, 2003).  The phosphorylation sites in protein kinases are the turn motif, activation loop 
and the hydrophobic motif. Furthermore, dephosphorylation consists of conformational 
modifications of the ABC kinases through exposing the phosphorylation sites which is regulated 
by the phosphatases (Newton, 2003).  
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Significance of protein kinases in Plasmodium 
The Plasmodium species life cycle is complex and it utilizes protein kinases as the major 
molecules in stimulating conversions of life stage (Kato, 2016). The parasite’s phosphorylation 
of cell protein kinases are involved in various and significant cellular mechanisms of cell cycle 
progression, transcription, translation, protein synthesis and apoptosis (Kato, 2016).  
The parasite genome database contains protein kinases data as kinome. Due to their 
importance in the life stage of parasite, these protein kinases are utilized as drug targets with no 
side effects in humans (Kato, 2016). As a second messenger, calcium plays a significant role at 
different life cycle stages of P. falciparum in cascades of multiple signaling (Bansal, Molina-
Cruz, Brzostowski, Mu, & Miller, 2017). These calcium dependent protein kinases of P. 
falciparum are regulators of transduction pathways, merozoites egress from mature schizonts, 
merozoites invasion into erythrocytes and motor proteins phosphorylation (Bansal et al., 2017).  
The necessity to understand the mechanism of resistance in P. falciparum to anti-malarial 
drugs converges to the biology of the parasite proliferation. The chemogenomic whole-cell 
methods of Plasmodium species analysis have identified potential targets from critical pathways 
of the life cycle of the parasites (Pradhan et al., 2015). The wild type NF54 of PF3D7_1305500 
disruption of the gene significantly inhibited the blood-stage growth (Balu et al., 2013).  
Eukaryotic cells possess a regulatory mechanism of protein phosphorylation for the 
control of their cellular processes. Furthermore, the relationship between signaling pathways, 
protein kinases and their substrates provides significant information regarding the mechanism of 
disease. Despite progress in understanding protein kinases in mammalian cells, malarial parasite 
protein kinases are still in its early stage. There are approximately 100 protein kinases in P. 
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falciparum that are involved in phosphorylation of asexual blood stage of the malarial parasite 
(Alam et al., 2015).  
Apart from that, protein kinases from P. falciparum have 35-60% sequence identity to 
mammalian orthologous and lack tyrosine kinases that provides potential target for specific 
inhibition. Even though 36 out of 65 protein kinases are potential targets for drug screening but 
still there is none developed to clinical studies and application (Hallyburton et al., 2017).  
The protein receptor for Activated C-Kinase 1 (PfRACK1) in P. falciparum is expressed 
in blood stages of the parasite and is localized in cytoplasm. This protein has been shown to be 
potential target as it is involved in anchoring, cell migration, cytokinesis, transcription, 
epigenetics and protein translation (Blomqvist, DiPetrillo, Streva, Pine, & Dvorin, 2017). Protein 
kinase G with the up regulation of calcium dependent protein kinase 1 (PfCDPK6) and various 
other kinases compensate the decreased activity of CDPK1 in mutant malarial parasite. 
Furthermore, this indicates targeting a kinase causes modification in other kinases to compensate 
for the loss of function. So, combinational inhibition of two kinases can provide treatment 
regimen (Bansal et al., 2016). Moreover, calcium-dependent protein kinases of P. falciparum are 
essential at different stages of the life cycle but humans lack these kinases (Bansal et al., 2017).  
Furthermore, phosphorylation of Apical Membrane Antigen-1 (PfAMA-1) and 
reticulocyte binding-like homolog protein (PfRh) by P. falciparum protein and casein kinases 
respectively are involved in parasite invasion (Tham et al., 2015). After the invasion and parasite 
growth, the intracellular development of the parasite involves DNA replication in the middle of 
the process. There are several steps of DNA replication and nuclear division without cytokinesis 
that entails a multinucleated cell in the schizont stage of the parasite (Ganter et al., 2017).  
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During the process of DNA replication, there is specific kinase PfCRK4 involved in 
schizogony and is essential for the development in the mosquito. Hence, this kinase is essential 
for intraerythrocytic stage of infection and transmission of the parasite (Ganter et al., 2017). 
Hence, phosphorylation plays an important part in the development of different stages of 
parasites.  
As protein kinases in P. falciparum are potential targets for anti-malarial drugs, 14,000 
cell-active compounds were biochemically screened. Several novel inhibitors were found against 
three kinases namely, CDPK1, CDPK4 and PK6 with little effects on 150 human kinases 
(Crowther et al., 2016). Furthermore, Malaria Box provides around 25,000 compounds with a 
potential mechanism of action of 130 compounds against malaria that provide a library for 
malaria drug development. Among these compounds include specific P. falciparum kinase 
inhibitors (Van Voorhis et al., 2016). Different compounds have been studied and found for their 
kinase specific inhibitor properties (Huang et al., 2016; Ojo et al., 2014; Vidadala et al., 2014).  
 
Aim of the study 
The aim of this study is to partially characterize PfABCk2 protein kinase utilizing molecular 
cloning, heterologous express, protein kinase activity assay and targeted screening of protein 
kinase inhibitors. Furthermore, to express recombinant PfABCk2 in order to search for potential 
inhibitors utilizing the chemical compound database. Specifically, the aim is to construct 
recombinant PfABCk2 conserved region through molecular cloning and then evaluate 
heterologous expression of PfABCK2 in E. coli and purify the recombinant protein using Nickel 
affinity column chromatography. 
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CHAPTER TWO 
MATERIALS AND METHODS 
Molecular Cloning 
 
Selection of conserved domain 
 
PfABCk2 is a protein kinase that belongs to ABC family (ABCk2) encoded by PF3D7_1414500 
located on P. falciparum chromosome 14 (PlasmoDB, 2017). The complete DNA sequence 
length is 8277 bp and the protein sequence length is 2758 amino acids with a molecular weight 
of 326 kDa. The full DNA sequences of related Plasmodium species protein kinase were 
obtained from BLASTN to select for orthologs. The multiple sequence alignment was prepared 
from these sequences using CLUSTAL 2.1. The conserved region was selected using the 
Conserved Domains Database (CDD).  
 
DNA sequence of PfABCk2 with conserved domain for partial characterization 
 
TTTGGATCCATGAATCAATATGATCAATGGAATCGTAGAATTCGGACAATATGGTACTGT 
AGTAGTCTGTATGTAGAATATAAGAACGCTTTGAGGAAATCCAAAAAAATGCCGGTGGAG 
AAAAAAAAT GAATACTGGGAAAAGAAGCATGAAGAATTTGCTACAAAGATGTTAAATAA 
TATATATGAA TTAAGAGGTTGGTGGGTTAAAGTAGGACAATTTTTAAGTACCCAGGAAA 
ATATCATGCCTGTTGCTTATATAGAAAAATTTACGAAGCTGCAAGATATGATGCCTACGT 
CTTCATTTGATAAAATAGAAAATATTTTAAAAAAGGAATTAGGTAACATTTATGAAATGT 
TTGAATACATCGATAAAGAACCACTAGCTAGCGCTTCCATTGGACAAGTACATAAAGCGA 
AATTAAAAAAATATGATAAACATATATGCGATATAGACAGTAGAAAGCATAAGGATTATA 
ATGTAATAATAAAAATTCAACATGAAGGAATAGATCAGTTTTTGTCATCAGATATAAGTA 
CTTTAAAAAAAGTGTCTTGGGCATTTGGATTAATAGATAAGAATTTTTATTTTACAGATT 
TTATAGATGAATGGCAAGATTCTGCTTCTCGAGAATTAAATTATAAATATGAATTATATC 
ATCAATTGTTAGCTTATAACAGTTTTAAAAAATCAGGTATCCCTGTAAAAATACCTAAAA 
TTTATTGTGCTCATACAACTTCTAAGGTATTGGTTATGGAATATATTAAAGGCTTTAAAA 
TAACTGATACTGAATTACTTAAAAAATATAATGTAGATACATATAAAATGGTCTATAAAA 
TTATTGACTATTTTGCTTATCAAATACATAATGATGGTTTTTTTCATGGGGACCCACATC 
CGGGAAATATAGAGCTCAAA 
Conserved region (highlighted blue): 89-303bp 
Size of the conserved region: 214bp 
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Extension including conserved region: 900bp 
 
Restriction Enzymes: 
The restriction sites for BamH1 and Xho1 were included the primers for subsequent cloning and 
additions of TTT at 5’end and AAA at 3’end (reversed for primer design) were included. 
 
Forward Primer: TTTGGATCCATGAATCAATATGATCAATGG 
Reverse Primer: AAAGAGCTCTATATTTCCCGGATGTGG 
Product Length: 918bp 
 
Primer Name %GC Strand Size (bases) Tm (°C) 
PfABCk2  F 30.43 FWD        23              59.14 
PfABCk2  R 39.13 REV        23              58.74 
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Protein sequence of PfABCk2 
 
 
 
Conserved region (highlighted blue) from 124 to 302 amino acid 
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Polymerase Chain Reaction (PCR) 
Genomic DNA of P.  falciparum NF54 with a concentration of 241 ng/µl was used as a template 
using KOD Hot start DNA polymerase (Merck) to amplify PfABCk2. The cycling conditions 
were polymerase activation at 95ºC for 3 minutes that was followed by 45 cycles of denaturation 
at 95ºC for 20 seconds; annealing temperature at 56ºC for 10 seconds; extension at 70ºC for 15 
seconds and final extension at 70ºC for 10 minutes. The PCR product was verified on 1% 
agarose gel in 1X Tris acetate EDTA (TAE) buffer that was run at constant 160 volts. 
 
Purification of PCR product 
The PCR product was purified by QIAquick PCR purification kit (Qiagen). Firstly, added 250µl 
of Buffer PB to 50µl of the PCR reaction and mixed. Then QIAquick column was placed in 
collection tube and applied the sample to the column. Centrifuged for 1 minute at 10,000rpm. 
Afterwards, discarded the flow-through and to wash 750µl Buffer PE was added to the column. 
Centrifuged the column for 1 minute at 10,000rpm. After wash buffer is removed, the column 
was centrifuged at 10,000rpm for 1 minute. Afterwards, transferred the column to a 1.5ml 
microcentrifuge tube. The elution of DNA was performed by adding 50µl of nuclease free water 
on top of the membrane of the column and centrifuged at 10,000rpm for 1 minute. 
 
Plasmid construct  
The plasmid construct PfABCk - pET21a+ is synthesized utilizing OptimumGene codon 
optimization of GenScript. The codon optimization is performed to increase the gene expression 
efficiency and it includes GC content, mRNA secondary structure, codon usage bias, CpG 
dinucleotides content, premature PolyA sites, repeat sequences, RNA instability motif (ARE), 
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cloning interfering restriction enzyme sites and cryptic splicing sites. The codon usage bias is 
adjusted in E.coli, optimized and upgraded the codon adaptation index (CAI) from 0.36 to 0.95 
 ( >0.8 is optimum) for high gene expression level. The GC content is adjusted from 27.50% to 
46.40% as ideally it should be 30-70%. The restriction enzymes and CIS-acting elements are 
optimized for BamH1, Xho1, frameshift element, PolyT and PolyA. The repeat sequences are 
removed and unfavorable peaks are optimized to increase the half-life of the mRNA. 
Furthermore, the stem-loop structures are broken that effect stability and ribosomal binding of 
mRNA.   
 
Transformation with chemically competent E. coli 
BL-21 (DE3) pLysS competent E.coli (Invitrogen) were used for transformation. One vial per 
plasmid was transferred from -80ºC freezer and thawed on ice for 20 minutes. Afterwards, 5µl of 
the plasmid DNA was added into each vial of BL-21 (DE3) pLysS cells and mixed it gently by 
tapping. Then, the vial was incubated on ice for 30 minutes. Then, the cells were treated to heat-
shock for 30 seconds at 42ºC without shaking in a water bath. After this, the vial was removed 
immediately from the water bath and placed on ice for 2 minutes. Then, aseptically added 250µl 
of SOC medium to the vial. The vial was capped tightly and shaken horizontally at 37ºC for 1 
hour at 225rpm in a shaking incubator.  
During this time, Luria-Bertani (LB)-agar-ampicillin culture plates were pre-warmed 
at 37ºC. After 1 hour, the vial is taken out of the shaking incubator and aseptically spread 250µl 
cell suspension on LB-agar-ampicillin plate until dried. Then the plate was inverted and 
incubated for overnight (16-17 hours) in an incubator at 37ºC. The next day, the colonies appear 
on the plates. The plates are transferred to refrigerator at 4ºC. 
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Subculture 
LB-Broth containing ampicillin is prepared. The LB-broth in deionized water is autoclaved and 
after cooling down, transferred ampicillin. The LB-broth-ampicillin 3ml is transferred to 15ml 
falcons for culture. Colonies on the LB-agar-ampicillin culture plates were labeled. Then these 
colonies were picked with the help of white tip and transferred to their respective labeled tubes. 
The tubes were transferred to a shaking incubator at 37ºC for overnight (16-17 hours) for 
continuous shaking at 225rpm vertically in a tube stand. 
 
Minipreps DNA purification 
After overnight incubation with shaking, the tubes are centrifuged at 4000rpm for 5 minutes. The 
supernatant was discarded and each cell pellet was re-suspended with 250µl of cell re-suspension 
solution. Then transferred the cell suspension to their respective eppendorf and added 250µl of 
cell lysis solution to each sample. Furthermore, inverted the eppendorf 4 times to mix and added 
10µl alkaline protease solution. After this, inverted the tubes 4 times to mix and incubated for 5 
minutes at room temperature. To this solution, added 350µl of Neutralization solution and 
inverted 4 times to mix it. Centrifuge at 4000rpm for 10 minutes at room temperature. 
The spin column from the kit was inserted into collection tubes. After centrifugation, the 
cleared lysate was decanted into respective spin columns. Centrifuged these spin columns at 
4000rpm for 1 minute at room temperature. Then, the flow through was discarded and the 
columns reinserted into collection tubes. Furthermore, added 750µl of wash solution containing 
ethanol and centrifuge at 4000rpm for 1 minute. The flow through was discarded and the 
columns reinserted into collection tube. Then added 250µl of wash solution containing ethanol 
and centrifuge at 4000rpm for 2 minutes at room temperature.  
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Afterwards, centrifuge the spin columns for 1 minute at 4000rpm to remove any wash 
solution remnants. These spin columns are transferred to a sterile 1.5ml microcentrifuge tube and 
added 50µl of nuclease free water and let it stand for 1 minute. Centrifuged the spin column with 
microcentrifuge tube at 4000rpm for 1 minute at room temperature. The column was discarded 
and DNA was processed for Nanodrop estimation. 
 
Agarose gel  
The 1% agarose gel is prepared by weighing 1gm of agarose in 100ml of Tris-Acetate EDTA 
(TAE). The solution is heated in microwave oven for 3 minutes while continuously stirring to 
mix. After it is solubilized, the solution is cooled down and added 10µl of GelRed Nucleic Acid 
Gel Stain (Biotium). This solution is poured into gel assembly with 10 well comb and solidified. 
The samples are prepared in loading dye and loaded onto wells of agarose gel with 1kB DNA 
ladder. The agarose gel is run at 100 volts. 
 
Heterologous expression and protein purification  
The plasmid construct of PfABCk2 gene in pET21a+ expression vector with His-tag at C-
terminus is transformed into BL-21 (DE3) pLysS competent cells that is verified through 
Miniprep and DNA sequencing for the correct orientation and sequence of recombinant gene, 
DNA is analyzed with DNA sequencing. Furthermore, this gene construct is utilized to 
heterologous express.  
After validation of the sequence of PfABCK2- pET21-a+ construct in competent cells 
clones are picked from LB-agar-ampicillin culture plates. The selected clone is subculture in 3 
ml LB-broth-ampicillin media vertically in a tube stand in a shaking incubator at 37ºC for 
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overnight (16-17 hours) for continuous shaking at 225rpm. Afterwards, the overnight subculture 
1ml is transferred to autoclaved 400ml LB-broth-ampicillin media in a 2L flask culture and 4L 
for large-scale heterologous expression. The optimum growth is verified until it reaches the 
Optical Density (OD) at 600 nm to 0.6 against a blank (LB Broth medium). The culture flasks 
are transferred to a shaking incubator at 37ºC for continuous shaking at 225rpm till the OD 
reaches between 0.6 to 0.8 against a blank media.  
When the OD of the culture reaches 0.8, induction is initiated with a final concentration 
of 1mM IPTG at a temperature of 30°C for 3 hours. The culture is harvested with centrifugation 
at 8,000 rpm for 10 minutes at 4ºC. The supernatant is discarded and the cell pellet is stored at    
-80ºC till further processing. 
 
Isolation of protein from inclusion bodies 
The recombinant protein is expressed and located in inclusion bodies. Therefore, re-
suspend the cell pellet in 20ml ice-cold lysis buffer containing 20mM Phosphate pH 7.6 containing 
0.5 M NaCl, 25mM Imidazole with the addition of 500µg/ml lysozyme and 20µg/ml DNase to 
perform cell lysis. Sonicate the suspension on ice and centrifuge the cell lysate at 14,000 rpm for 
30 min. at 4°C.  
The cell pellet is solubilized in solubilizing buffer that consists of 50mM phosphate buffer 
containing 0.5M NaCl, 20mM Imidazole, 6M Guanidine HCl, overnight at room temperature with 
constant shaking. Centrifuge the cell lysate at 14,000 rpm for 15 min. at 4°C. The supernatant is 
removed and the supernatant is centrifuged again. The supernatant pH is adjusted to 7.6 – 7.8 and 
afterwards it is passed through a 0.45µM filter membrane. The protein purification with nickel 
affinity column is performed (An, Cao, & Xu, 2016; Chaitanyakumar & Anbalagan, 2016).  
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Nickel-NTA Affinity chromatography 
The nickel-NTA affinity chromatography is utilized to purify the recombinant protein due 
to His-tag at C-terminus. The HisPur Ni-NTA resin (Thermo Scientific) is equilibrated with 
binding buffer which consists of 50mM phosphate pH 7.8 containing 8M urea, 0.5M NaCl and 
10mM imidazole for 15 min. at room temperature, prior to loading of supernatant.  
Simultaneously, the solubilized protein is equilibrated in binding buffer for 1-hour at room 
temperature with continuous shaking. Subsequently, the supernatant is loaded onto the nickel-
NTA filled column and flow through is collected.  
The unbound protein is washed through with 10 column volumes of binding buffer. The 
bound protein is eluted with elution buffer consisting of 50mM phosphate buffer pH 7.8 containing 
8M urea, 0.5M NaCl and 250mM imidazole.  
The fractions are collected in 1ml volume each at the end of affinity chromatography. The 
protein estimation is performed at 280nm using Nanodrop. Furthermore, the selected fractions are 
analyzed on 10% SDS-PAGE for purity with reducing conditions for validation. The purified 
protein is stored at 4ºC until further use.  
 
Sodium Dodecyl Sulfate – Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE resolving and stacking gel are prepared using standard methods (Laemmli, 1970).  
Materials: 
1. Acrylamide/Bis 
2. 1.5M Tris-HCL pH 8.8 
3. 0.5M Tris-HCL pH 6.8 
4. 10 % Sodium Dodecyl Sulfate (SDS) 10g/100 ml deionized water. 
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5. 10 % Ammonium persulfate (APS) freshly prepared 0.1g/1ml in deionized water.  
6. TEMED 
7. Deionized water 
 
10% Resolving gel  
Table 1: Composition of 10% resolving gel of SDS-PAGE 
Components Volume for 2 gels 
Acrylamide/Bis 3 ml 
Deionized water 4.3 ml 
1.5 M Tris-HCL pH 8.8 2.5 ml 
10% SDS 100 µl 
10% APS 100 µl 
TEMED 15 µl 
 
5 % Stacking gel 
Table 2: Composition of 10% stacking gel of SDS-PAGE 
Components Volume for 2 gels 
Acrylamide/Bis 0.625 ml 
Deionized water        0.79 ml 
1 M Tris-HCL pH 6.8 3.5 ml 
10% SDS  50 µl 
10% APS 50 µl 
TEMED 9 µl 
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10X Running buffer  
Table 3: Components of 10X running buffer 
Component Amount 
Tris 30g/L 
Glycine 144g/L 
Deionized water   Make up to 1L 
        
1X Running buffer pH 8.3 
Table 4: Components of 1X running buffer pH 8.3 
Components for 2 L Volume 
10% SDS 20ml 
Tris/Glycine 200ml 
Deionized water up to 2L 
 
Coomassie staining 
Table 5: Components of Coomassie staining solution 
Components Amount 
Coomassie brilliant 
blue R-250 
1g/L 
Ethanol 400 ml/L 
Acetic acid 100 ml/L 
Deionized water                                         500 ml/L 
                
Coomassie brilliant blue R-250 is dissolved in ethanol and subsequently acetic acid and deionized 
water added after Coomassie is completely solubilized and volume made up to 1 Liter. 
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Destaining solution 
Table 6: Composition of destaining solution 
Components Volume 
Ethanol 400 ml/L 
Acetic acid 100 ml/L 
Deionized water 500 ml/L 
 
The small and large glass plates, assembly and comb are cleaned with ethanol to remove 
any contamination. The glass plates are carefully placed inside the assembly, fixed and verified 
for any leakage using water. The resolving gel mixture immediately poured carefully in between 
glass plates taking care not to let air bubbles in the solution with overlay of deionized water to 
inhibit oxygen. The resolving gel is let polymerized from 15 to 20 minutes.  
After the resolving gel is polymerized, stacking gel mixture is poured on top of the 
resolving gel after removing water and immediately added comb with wells on top of it till 
completely immersed between plates. The polymerization time is 45 minutes and meanwhile, the 
protein samples are prepared after protein estimation. Reducing sample diluting buffer with beta-
mercaptoethanol is added to samples and boiled at 95ºC for 5 minutes. The samples are centrifuged 
and loaded onto respective wells with protein molecular marker. The assembly with glass plates is 
filled with running buffer in upper and lower reservoir.  
The electrode are attached into power supply and run at constant voltage of 160 volts until 
bromophenol blue boundary reaches the bottom of the gel. The gel is carefully removed from the 
assembly and stained in Coomassie staining solution for 20 minutes and then destained. 
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Optimization of induction conditions  
The different optimization conditions for induction are performed utilizing following parameters:  
1. 1mM IPTG induction for 1 hour, at 30°C  
2. 1mM IPTG induction for 3 hour at 20°C  
3. 0.5 mM IPTG induction for 3 hour at 30°C 
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CHAPTER THREE 
RESULTS 
PfABCk2 bioinformatic analysis 
The protein kinase of P. falciparum PF3D7_1414500 belongs to the ABC-1 family of proteins.  
The PfABCK2 analysis of proteome during intraerythrocytic development shows that this 
protein is abundantly found in trophozoites and schizonts forms of the P. falciparum (PlasmoDB, 
2017). Based upon our lab’s recent analysis for gene essentiality, using piggyBac saturation 
mutagenesis, PF3D7_1414500 is essential (MIS = 2032) for asexual intraerythrocytic survival 
and there is even a significant fitness cost (MFS = 2514 ) for mutations in the UTR flanking 
sequences (Zhang et al., 2018). Furthermore, the life cycle expression of this protein is highest in 
late schizonts (LS) and gametocytes as compared to the mRNA half-life that is highest in 
schizonts at 40 minutes. Apart from this, the post-translational modification data indicates there 
are two specific amino acids namely serine (S) and threonine (T) in phosphorylation site which 
are involved in phosphorylation of substrate (PlasmoDB, 2017). 
The conserved region of PfABCK2 is selected after the Conserved Domains Database 
(CDD) analysis (Figure 3). Phylogenetic tree of PfABCk2 in relation to human protein kinases 
shows that it has less than 30% identity (Figure 4). The full DNA sequences of related 
Plasmodium species protein kinase obtained from BLASTN and multiple sequence alignment is 
performed using CLUSTAL 2.1 that shows conserved region (Figure 5).  
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Figure 3: Conserved Domains Database (CDD) analysis for PfABCk2 shows the conserved region 
of ABC family of kinases from 89-303. 
 
Figure 4: Phylogenetic tree of PfABCk2 in relation to human protein kinases showing less than 
30% identity. 
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Figure 5: Multiple sequence alignment of related Plasmodium species shows protein kinase 
conserved region highlighted in red boxes. Red arrow indicates the PfABCk2 sequence. 
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Molecular cloning of gene construct PfABCk2-pET21a+ 
After transformation of gene construct PfABCk2-pET21a+ into BL-21 (DE3) pLys competent 
cells, the white colonies appeared in the selective agar plates. This indicates the successful 
transformation of construct into competent cells. The agarose gel verified the expected band of 
PfABCk2 at around 1000bp that validates the gene of interest and is in correct orientation by 
using restriction enzymes BamH1 and Xho1 on construct obtained from clones (Figure 6).   
                        
                               
Figure 6: PfABCk2 on 1% agarose gel in Tris-Acetate EDTA. Lane 1: 1Kb DNA Ladder (6μl), 
Lane 2: Empty, Lane 3: PfABCk-pET21a+ construct (5μl), after transformation of PfABCk-
pET21a+ into competent cells Lane 4: Clone A6 uncut construct (10μl), Lane 5: Clone A6 cut with 
restriction enzymes BamH1 and Xho1 (B/X) (10μl), Lane 6: Clone B5 uncut construct (10μl), Lane 
7: Clone B5 cut with restriction enzymes BamH1 and Xho1 (B/X) (10μl) loaded on gel. Run at 
constant 160 volts.                           
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Nickel-NTA affinity chromatography 
PfABCk-pET21a+ gene construct is utilized to express this protein in BL-21 (DE3) pLys 
competent cells with a final concentration of 1mM IPTG at a temperature of 30°C for 3 hours. The 
recombinant protein PfABCk is localized in inclusion bodies. This indicates the protein is 
insoluble therefore it is not present in the supernatant. Afterwards, the recombinant protein kinase 
is purified using nickel-NTA affinity chromatography (Figures 7).   
 
Figure 7: Ni-NTA affinity purification of recombinant PfABCk2 with His-tag on C-terminus using 
elution buffer containing from 10mM to 250mM Imidazole. 
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SDS-PAGE analysis of recombinant protein purification 
The recombinant protein kinase fractions purified using nickel affinity chromatography on 10% 
SDS-PAGE with different steps of isolation and purification with the expected 36 kDa protein 
band as shown (Figure 8 and 9).  
 
Figure 8: 10% Resolving gel of PfABCk heterologous expression in BL-21 (DE3) Lys competent 
cells. Lane 1: Protein Marker (Bio-Rad) 5μl, Lane 2: Empty, Lane 3: Whole cell lysate, Lane 4: 
Empty, Lane 5: supernatant, Lane 6: Empty, Lane 7: supernatant of cell pellet, Lane 8: solubilized 
cell pellet. 
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Figure 9: 10% Resolving gel after nickel affinity chromatography. Lane 1: Empty, Lane 2: Protein 
Marker (Bio-Rad) 5μl, Lane 3: Empty, Lane 4: Fraction 4, Lane 4: Fraction 5, Lane 5: Fraction 6, 
Lane 6: Fraction 7, Lane 7: Fraction 8, Lane 8: Fraction 9. 
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Optimization of induction conditions  
 
 
Figure 10: 10% Resolving gel of PfABCk optimization conditions. Lane 1: Protein Marker (Bio-
Rad) 5μl, Lane 2: empty, Lane 3: 1mM IPTG induction for 1 hour at 30°C solubilized inclusion 
bodies , Lane 4: empty, Lane 5: 1mM IPTG induction for 3 hour at 20°C solubilized inclusion 
bodies, Lane 6: empty, Lane 7: 0.5 mM IPTG induction for 3 hour at 30°C solubilized inclusion 
bodies, Lane 8: empty, Lane 9: empty. 
 
The bioinformatic analysis of PfABCK2 showed that this protein belongs to the ABCk 2 family 
of protein kinases. The PfABCK2 analysis of proteome during intraerythrocytic development 
shows that this protein is abundantly found in trophozoites and schizonts forms of the P. 
falciparum. Furthermore, piggyBac saturation mutagenesis shows it to be essential (MIS = 2032) 
for asexual intraerythrocytic survival with a significant fitness cost (MFS = 2514) for mutations 
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in the UTR flanking sequences. Hence, the gene of PfABCk2 was ligated into pET21a+ 
expression vector with His-tag at C-terminus and transformed into BL-21 (DE3) competent cells 
that were verified through Miniprep and DNA sequencing. Furthermore, this gene construct is 
utilized to heterologous express this protein with 1mM IPTG at a temperature of 30°C for 3 
hours and afterwards purified the recombinant protein kinase using nickel affinity 
chromatography as shown on 10% SDS-PAGE with the expected 36 kDa protein band. 
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CHAPTER FOUR 
DISCUSSION 
 
Malaria is a major risk to public health and search for potential therapeutic targets in P. 
falciparum is important to reduce the infection and consequent mortality globally. The emerging 
resistance of P. falciparum to current anti-malarial drugs has stressed the importance of 
discovery, development and application of novel therapeutic drugs against malaria (Hallyburton 
et al., 2017). Recently, the search for novel therapeutic targets drug discovery efforts have 
steered towards proteins such as proteases and kinases, since they have functionally-defined 
biological processes. Among the protein kinases in Plasmodium species (Hallyburton et al., 
2017). The kinome of Plasmodium consists of 85-99 protein kinases, out of which 20 are FIKK 
family and 65 are eukaryotic protein kinases. Moreover, Plasmodium kinases have 35-60% 
sequence identity to mammalian orthologous (Hallyburton et al., 2017).  
Furthermore, Plasmodium kinome contain only serine/threonine kinases and as compared 
to human kinome, Plasmodium kinome lack tyrosine kinases  therefore that provides potential 
target for specific inhibition (Solyakov et al., 2011; Tewari et al., 2010).  There are 36 from 65 P. 
falciparum eukaryotic protein kinases that are genetically proven to be therapeutic target and 
there are no inhibitors found to proceed into clinical applications (Hallyburton et al., 2017).  
Furthermore, protein kinases of P. falciparum mechanism of action and biology is still in 
embryonic stage (Hallyburton et al., 2017). Therefore, the focus of this study is a P. falciparum 
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protein kinase PfABCk2 that plays an essential role in phosphorylation of different proteins in 
asexual blood stage of the parasite.  
The aim of the study is to partially characterize the conserved region of protein kinase of 
PfABCk2. Therefore, the gene construct of PfABCk2 is ligated into pET21a+ expression vector 
with His-tag at C-terminus and transformed into BL-21 (DE3) pLysS competent cells. The 
transformation and construct orientation is verified through Miniprep and DNA sequencing. This 
indicates the successful transformation of construct into competent cells.  
The gene construct of PfABCk2- pET21a+ in BL-21 (DE3) competent cells is utilized to 
express this recombinant protein with 1mM IPTG induction at 30°C for 3 hours. The 
recombinant protein kinase is expressed in inclusion bodies rather than as soluble protein in 
cytosolic fraction of the whole cell lysate. 
 Furthermore, the recombinant protein kinase is isolated from inclusion bodies utilizing 
lysis buffer containing 20mM Phosphate pH 7.6 containing 0.5 M NaCl, 25mM Imidazole with 
the addition of 500ug/ml lysozyme and 20ug/ml DNase to perform cell lysis. The cell pellet 
containing inclusion bodies is solubilized in solubilizing buffer that consists of 50mM phosphate 
buffer containing 0.5 NaCl, 20mM Imidazole, 6M Guanidine HCl.   
The recombinant protein is purified using nickel affinity chromatography due to the 
presence of His-tag on C-terminus. The His-tag on recombinant protein binds to nickel and 
concomitant substitution with increasing concentration of imidazole, the recombinant protein 
with His-tag is eluted as purified protein. After purification, the concentration and yield of 
PfABCk2 is estimated to be 3.29 mg from 4L culture.  
The future work will be focused on PfABCk2 characterization to utilize it as a potential 
therapeutic target. This characterization will encompass utilization of GFP tagged PfABCk2 to 
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localize this protein in P. falciparum and furthermore the determination and verification of this 
tagged protein with the assistance of mass spectrometry. Moreover, to isolate PfABCk2 with 
pull-down assay to specifically purify this protein from whole cell lysate. Eventually, antibody 
generation from purified protein will be proceeded with this recombinant protein purified from 
this study. Furthermore, PfABCK2 can be used as a therapeutic target due to its higher 
expression during the late schizont stage of blood stage form.  
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Appendix A 
 
WHO permission 
Permissions and licensing 
Permissions 
WHO exercises copyright over its information to make sure that it is used in accordance with the 
Organization's principles. Extracts of WHO information can be used for private study or for 
educational purposes without permission. Wider use requires permission to be obtained from 
WHO. 
• Extracts from WHO information  
• Links to and from the WHO website  
• The WHO emblem  
Licensing 
WHO licenses its published material widely, in order to encourage maximum use and 
dissemination. If you are interested in obtaining a licence (either commercial or non-commercial) 
from WHO, please click on the links below for more information and the applications procedure. 
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Appendix B 
CDC permission 
Life cycle of Plasmodium species in Anopheles mosquito and human host  
General Use of Government Content 
Information and images developed by CDC and presented on the CDC website are works of the 
U.S. Government. This content may include: 
• general text information, 
• publications for download, or 
• graphs. 
CDC-generated works (including photographs, graphics, images, videos, PSAs) located on this 
site are in the public domain. This means that they are meant for public use and are not subject to 
copyright law protections. Permission is NOT required for use of public domain items. But, CDC 
does ask that you credit the agency and contributor whenever the item is used in any publicly 
distributed media. 
You are free to adapt and revise these materials, as long as you distribute the revised materials 
free of charge. But, if you make changes or revisions, you must remove the CDC name and 
logo from the materials. 
Use of Non-Government Content 
You may also find on the CDC website materials or products that are owned or were created by 
others. This content may include copyrighted materials and other materials provided by third 
parties, such as private companies or non-government organizations. These third parties retain all 
rights, including copyright, to publish or reproduce those documents/images, or to authorize 
others to do so. This is in accordance with Title 17, Sections 106 through 120 of the U.S. Code. 
Any copyrighted materials included on the CDC website were used with the permission of the 
copyright holder and are NOT in the public domain. These materials remain the property of their 
respective owners or creators, and should NOT be reproduced or otherwise used. 
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For more information, please visit the CDC website: 
CDC Resources 
Using CDC.gov: Policies and Regulations 
Office of the Associate Director for Communication, Division of Public Affairs 
http://www.cdc.gov/Other/policies.html 
CDC Newsroom FAQs: Are CDC materials on the web copyrighted? 
Centers for Disease Control and Prevention 
https://www.cdc.gov/media/subtopic/questions.htm#5 
 
***Feedback about your experience with CDC-INFO is important to us and will help us 
continue to improve. Please rate your interaction by completing this short survey:  
https://www.surveymonkey.com/r/FKXRCG5?CaseId=CDC-12671-M0B1Y4 
Responses are kept completely confidential.*** 
 
Links to nonfederal organizations are provided as a service. Links are not an endorsement of 
these organizations or their programs by CDC or the federal government. CDC is not responsible 
for the content of organization websites found at these links. 
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respond to replies sent to this mailbox. If you have questions or comments, please send them via 
our online form at www.cdc.gov/info. 
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